Sugi Predict

Sugi Predict / Compounds / SCHEMBL2646714

SCHEMBL2646714

SCHEMBL2646714

CCOC(=O)c1csc(NC(=O)C(CC2CCCC2)c2cccc(Cl)c2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ SMN1; SMN2 Q16637 5/20 0.53
▸ LMNA P02545 3/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ ANO1 Q5XXA6 1/20 0.49
▸ EGFR P00533 1/20 0.48
▸ RAB9A P51151 5/20 0.47
▸ NPC1 O15118 4/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ HSP90AA1 P07900 3/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ GAA P10253 2/20 0.44
▸ CTSK P43235 1/20 0.43
▸ GCK P35557 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ FFAR2 O15552 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2644873 0.92 L3MBTL1 (0.46) L3MBTL1SMN1; SMN2GCKFFAR2
SCHEMBL2658530 0.92 L3MBTL1 (0.46) L3MBTL1SMN1; SMN2GCKFFAR2
SCHEMBL2662519 0.90 SMN1; SMN2 (0.51) L3MBTL1SMN1; SMN2LMNAANO1EGFR
SCHEMBL2646731 0.89 SMN1; SMN2 (0.57) L3MBTL1SMN1; SMN2LMNAMAPK1ANO1
SCHEMBL2646555 0.89 SMN1; SMN2 (0.54) L3MBTL1SMN1; SMN2LMNAMAPK1ANO1
SCHEMBL27548008 0.87 FFAR2 (0.46) L3MBTL1GCKFFAR2
SCHEMBL2646718 0.86 MAPT (0.59) SMN1; SMN2LMNAMAPK1RAB9ANPC1
SCHEMBL14435743 0.86 MAPT (0.59) SMN1; SMN2LMNAMAPK1RAB9ANPC1
SCHEMBL6563294 0.86 L3MBTL1 (0.41) L3MBTL1SMN1; SMN2LMNAGCKMAPT
SCHEMBL2648531 0.84 SMN1; SMN2 (0.55) SMN1; SMN2LMNARAB9ANPC1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951945-B2 Heteroaromatic glucokinase activators HOFFMAN-LA ROCHE INC. (US) 2005-10-04 — — US claimed
EP-1169312-B1 GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2004-10-06 — — EP claimed
CN-1151140-C Glucokinase activators - 2004-05-26 — — CN claimed
US-20040014968-A1 Heteroaromatic glucokinase activators BIZZARRO FRED THOMAS (US) 2004-01-22 — — US claimed
CN-1349519-A Glucokinase activators HOFFMANN LA ROCHE (CH) 2002-05-15 — — CN claimed
US-6320050-B1 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. HOFFMANN-LA ROCHE INC. 2001-11-20 — — US claimed
US-20010039344-A1 Heteroaromatic glucokinase activators HOFFMANN-LA ROCHE INC. 2001-11-08 — — US claimed
US-20070203207-A1 Heteroaromatic glucokinase activators BIZZARRO FRED T 2007-08-30 — — US disclosed
US-7223868-B2 Such as 2-(3-chloro-phenyl)-3-cyclopentyl-N-thiazol-2-yl-propionamide which increases insulin secretion in treatment of type II diabetes HOFFMANN-LA ROCHE INC. (US) 2007-05-29 — — US disclosed
US-20050261503-A1 Heteroaromatic glucokinase activators BIZZARO FRED T 2005-11-24 — — US disclosed
US-6951945-B2 Heteroaromatic glucokinase activators HOFFMAN-LA ROCHE INC. (US) 2005-10-04 — — US disclosed
EP-1169312-B1 GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2004-10-06 — — EP disclosed
CN-1151140-C Glucokinase activators - 2004-05-26 — — CN disclosed
US-20040014968-A1 Heteroaromatic glucokinase activators BIZZARRO FRED THOMAS (US) 2004-01-22 — — US disclosed
US-6610846-B1 Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide HOFFMAN-LA ROCHE INC. 2003-08-26 — — US disclosed
CN-1349519-A Glucokinase activators HOFFMANN LA ROCHE (CH) 2002-05-15 — — CN disclosed
EP-1169312-A2 GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-09 — — EP disclosed
US-6320050-B1 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. HOFFMANN-LA ROCHE INC. 2001-11-20 — — US disclosed
US-20010039344-A1 Heteroaromatic glucokinase activators HOFFMANN-LA ROCHE INC. 2001-11-08 — — US disclosed
WO-2000058293-A2 GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2000-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014968-A1 Heteroaromatic glucokinase activators GCKR, GCK, PDXK L3MBTL1 4069/4885SMN1; SMN2 4775/4885LMNA 4371/4885
US-20010039344-A1 Heteroaromatic glucokinase activators GCKR, GCK, PDXK L3MBTL1 4308/4885SMN1; SMN2 4774/4885LMNA 4339/4885
US-20070203207-A1 Heteroaromatic glucokinase activators GCKR, GCK, PDXK L3MBTL1 4069/4885SMN1; SMN2 4775/4885LMNA 4371/4885
US-20050261503-A1 Heteroaromatic glucokinase activators GCKR, GCK, PDXK L3MBTL1 4069/4885SMN1; SMN2 4775/4885LMNA 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.